Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060383 | 1.00 | TK2 (1.00) | TK2TK1 | |
| SCHEMBL31061074 | 1.00 | TK2 (1.00) | TK2TK1 | |
| SCHEMBL19196330 | 0.93 | TK2 (1.00) | TK2TK1 | |
| SCHEMBL12268297 | 0.79 | DUT (0.68) | TK2TK1 | |
| SCHEMBL913176 | 0.79 | DUT (0.68) | TK2TK1 | |
| SCHEMBL913645 | 0.77 | DUT (0.70) | TK2TK1 | |
| SCHEMBL19196301 | 0.76 | TK2 (1.00) | TK2TK1 | |
| SCHEMBL15110503 | 0.75 | TK2 (0.60) | TK2TK1 | |
| SCHEMBL6890252 | 0.74 | TK1 (0.65) | TK2TK1 | |
| SCHEMBL6883307 | 0.74 | TK1 (0.65) | TK2TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10940150-B2 | Thymine derivatives and quinazoline-dione derivatives for the inhibition of HSP27 | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2021-03-09 | — | — | US | disclosed |
| US-20180207160-A1 | THYMINE DERIVATIVES AND QUINAZOLINE-DIONE DERIVATIVES FOR THE INHIBITION OF HSP27 | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2018-07-26 | — | — | US | disclosed |
| US-20170216297-A1 | EFFICIENT INHIBITION OF HSP27 | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2017-08-03 | — | — | US | disclosed |
| US-20170216297-A1 | EFFICIENT INHIBITION OF HSP27 | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207160-A1 | THYMINE DERIVATIVES AND QUINAZOLINE-DIONE DERIVATIVES FOR THE INHIBITION OF HSP27 | HSPB1, HSP90B1, HSP90AB1 | TK2 898/4885TK1 213/4885 |
| US-20170216297-A1 | EFFICIENT INHIBITION OF HSP27 | HSPB1, HSP90AB2P, HSP90B1 | TK2 243/4885TK1 710/4885 |
| US-10940150-B2 | Thymine derivatives and quinazoline-dione derivatives for the inhibition of HSP27 | HSPB1, HSP90B1, HSP90AB1 | TK2 898/4885TK1 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.